A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease

IntroductionDespite significant progress, a disease-modifying therapy for Alzheimer’s disease (AD) has not yet been developed. Recent findings implicate soluble oligomeric amyloid beta as the most relevant protein conformation in AD pathogenesis. We recently described a signaling cascade whereby oligomeric amyloid beta binds to cellular prion protein on the neuronal cell surface, activating intracellular Fyn kinase to mediate synaptotoxicity. Fyn kinase has been implicated in AD pathophysiology both in in vitro models and in human subjects, and is a promising new therapeutic target for AD. Herein, we present a Phase Ib trial of the repurposed investigational drug AZD0530, a Src family kinase inhibitor specific for Fyn and Src kinase, for the treatment of patients with mild-to-moderate AD.MethodsThe study was a 4-week Phase Ib multiple ascending dose, randomized, double-blind, placebo-controlled trial of AZD0530 in AD patients with Mini-Mental State Examination (MMSE) scores ranging from 16 to 26. A total of 24 subjects were recruited in three sequential groups, with each randomized to receive oral AZD0530 at doses of 50 mg, 100 mg, 125 mg, or placebo daily for 4 weeks. The drug:placebo ratio was 3:1. Primary endpoints were safety, tolerability, and cerebrospinal fluid (CSF) penetration of AZD0530. Secondary endpoints included changes in clinical efficacy measures (Alzheimer’s Disease Assessment Scale – cognitive subscale, MMSE, Alzheimer’s Disease Cooperative Study – Activities of Daily Living Inventory, Neuropsychiatric Inventory, and Clinical Dementia Rating Scale – Sum of Boxes) and regional cerebral glucose metabolism measured by fluorodeoxyglucose positron emission tomography.ResultsAZD0530 was generally safe and well tolerated across doses. One subject receiving 125 mg of AZD0530 was discontinued from the study due to the development of congestive heart failure and atypical pneumonia, which were considered possibly related to the study drug. Plasma/CSF ratio of AZD0530 was 0.4. The 100 mg and 125 mg doses achieved CSF drug levels corresponding to brain levels that rescued memory deficits in transgenic mouse models. One-month treatment with AZD0530 had no significant effect on clinical efficacy measures or regional cerebral glucose metabolism.ConclusionsAZD0530 is reasonably safe and well tolerated in patients with mild-to-moderate AD, achieving substantial central nervous system penetration with oral dosing at 100–125 mg. Targeting Fyn kinase may be a promising therapeutic approach in AD, and a larger Phase IIa clinical trial of AZD0530 for the treatment of patients with AD has recently launched.Trial registrationClinicalTrials.gov: NCT01864655. Registered 12 June 2014.

[1]  S. Yen,et al.  Disease-related Modifications in Tau Affect the Interaction between Fyn and Tau* , 2005, Journal of Biological Chemistry.

[2]  D. Westaway,et al.  Aβ Inhibition of Ionic Conductance in Mouse Basal Forebrain Neurons Is Dependent upon the Cellular Prion Protein PrPC , 2011, The Journal of Neuroscience.

[3]  Haakon B Nygaard,et al.  Current and emerging therapies for Alzheimer's disease. , 2013, Clinical therapeutics.

[4]  M. Gobbi,et al.  Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein , 2010, Proceedings of the National Academy of Sciences.

[5]  J. Baselga,et al.  Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study. , 2012, Bone.

[6]  J. Baselga,et al.  Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors , 2010, Clinical Cancer Research.

[7]  Xinglong Wang,et al.  Cellular prion protein is essential for oligomeric amyloid-β-induced neuronal cell death. , 2012, Human molecular genetics.

[8]  S. Strittmatter,et al.  Fyn kinase inhibition as a novel therapy for Alzheimer’s disease , 2014, Alzheimer's Research & Therapy.

[9]  A. Palmeri,et al.  Picomolar Amyloid-β Positively Modulates Synaptic Plasticity and Memory in Hippocampus , 2008, The Journal of Neuroscience.

[10]  M. Rowan,et al.  Interaction between prion protein and toxic amyloid β assemblies can be therapeutically targeted at multiple sites , 2011, Nature communications.

[11]  G. Zamponi.  Faculty Opinions recommendation of Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. , 2009 .

[12]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[13]  M. Rowan,et al.  Alzheimer's Disease Brain-Derived Amyloid-β-Mediated Inhibition of LTP In Vivo Is Prevented by Immunotargeting Cellular Prion Protein , 2011, The Journal of Neuroscience.

[14]  Michael W. Weiner,et al.  Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: Findings from the Alzheimer's Disease Neuroimaging Initiative , 2010, NeuroImage.

[15]  A. Vortmeyer,et al.  Alzheimer Amyloid-β Oligomer Bound to Post-Synaptic Prion Protein Activates Fyn to Impair Neurons , 2012, Nature Neuroscience.

[16]  John W. Gilbert,et al.  Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-β Oligomers , 2009, Nature.

[17]  S. Strittmatter,et al.  Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an alzheimer's disease model mouse , 2010, BMC Neuroscience.

[18]  S. Strittmatter,et al.  Fyn inhibition rescues established memory and synapse loss in Alzheimer mice , 2015, Annals of neurology.

[19]  J. Cummings,et al.  The Neuropsychiatric Inventory , 1997, Neurology.

[20]  Hyoung-Gon Lee,et al.  Amyloid-β42 Interacts Mainly with Insoluble Prion Protein in the Alzheimer Brain* , 2011, The Journal of Biological Chemistry.

[21]  L. Otterbein,et al.  N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. , 2006, Journal of medicinal chemistry.

[22]  D. Bennett,et al.  The Complex PrPc-Fyn Couples Human Oligomeric Aβ with Pathological Tau Changes in Alzheimer's Disease , 2012, The Journal of Neuroscience.

[23]  H. Band,et al.  Tau interacts with src-family non-receptor tyrosine kinases. , 1998, Journal of cell science.

[24]  T. L. Brink,et al.  Clinical Gerontology: A Guide to Assessment and Intervention , 1986 .

[25]  S. Lipton,et al.  Aβ neurotoxicity depends on interactions between copper ions, prion protein, and N-methyl-d-aspartate receptors , 2012, Proceedings of the National Academy of Sciences.

[26]  Richard Eastell,et al.  Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double‐blind, placebo‐controlled, multiple‐ascending‐dose phase I trial , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[27]  F. Nicoletti,et al.  β-Amyloid Monomers Are Neuroprotective , 2009, The Journal of Neuroscience.

[28]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[29]  J. Morris.  The Clinical Dementia Rating (CDR) , 1993, Neurology.

[30]  J. Yesavage,et al.  Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version. , 1986 .

[31]  W. Klein,et al.  Aβ Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease , 2007, The Journal of Neuroscience.

[32]  Alun Williams,et al.  Amyloid-β-induced Synapse Damage Is Mediated via Cross-linkage of Cellular Prion Proteins , 2011, The Journal of Biological Chemistry.

[33]  S. Lindquist,et al.  The cellular prion protein mediates neurotoxic signalling of β‐sheet‐rich conformers independent of prion replication , 2011, The EMBO journal.

[34]  A. Vortmeyer,et al.  Metabotropic Glutamate Receptor 5 Is a Coreceptor for Alzheimer Aβ Oligomer Bound to Cellular Prion Protein , 2013, Neuron.

[35]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[36]  R. Katzman.,et al.  Pathological verification of ischemic score in differentiation of dementias , 1980, Annals of neurology.

[37]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[38]  Jennifer E. Podesta,et al.  Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia. , 2011, Leukemia research.

[39]  W. Klein,et al.  Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. , 2007, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[40]  G. V. Van Hoesen,et al.  Phosphorylation of Tau by Fyn: Implications for Alzheimer's Disease , 2004, The Journal of Neuroscience.

[41]  W. Surewicz,et al.  Interaction between human prion protein and amyloid-beta (Abeta) oligomers: role OF N-terminal residues. , 2010, The Journal of biological chemistry.

[42]  S. Strittmatter,et al.  Memory Impairment in Transgenic Alzheimer Mice Requires Cellular Prion Protein , 2010, The Journal of Neuroscience.

[43]  M. Sano,et al.  An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimer's Disease , 1997, Alzheimer disease and associated disorders.

[44]  N. Carragher,et al.  Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530 , 2009, Molecular oncology.

[45]  A. Aguzzi,et al.  Supplementary figure legends , 2010 .

[46]  T. Naoe,et al.  Trough plasma concentration of imatinib reflects BCR–ABL kinase inhibitory activity and clinical response in chronic‐phase chronic myeloid leukemia: A report from the BINGO study , 2010, Cancer science.

[47]  S. Yen,et al.  Tyrosine phosphorylation of tau accompanies disease progression in transgenic mouse models of tauopathy , 2010, Neuropathology and applied neurobiology.

[48]  L. Hugonot-Diener,et al.  Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial , 2011, Alzheimer's Research & Therapy.